Profile data is unavailable for this security.
About the company
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
- Revenue in EUR (TTM)17.59m
- Net income in EUR-88.47m
- Incorporated2000
- Employees235.00
- LocationCellectis SA8, rue de la Croix JarryPARIS 75013FranceFRA
- Phone+33 181691600
- Fax+33 181691606
- Websitehttps://www.cellectis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adocia SA | 2.15m | -21.16m | 82.74m | 78.00 | -- | -- | -- | 38.48 | -1.93 | -1.93 | 0.194 | -0.4908 | 0.0774 | 2.62 | 7.44 | 27,564.10 | -76.16 | -43.08 | -396.14 | -72.93 | 7.91 | -- | -984.28 | -514.53 | 1.01 | -2.07 | 2.12 | -- | -81.22 | -46.13 | -206.65 | -- | -27.60 | -- |
| Inventiva SA | 17.48m | -110.43m | 98.66m | 112.00 | -- | -- | -- | 5.64 | -2.45 | -2.45 | 0.3854 | -0.6146 | 0.1884 | -- | 9.18 | 156,044.60 | -116.84 | -54.30 | -207.08 | -69.98 | -- | -- | -620.31 | -669.97 | 0.9524 | -19.98 | 6.96 | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Maat Pharma SA | 2.23m | -19.72m | 101.60m | 50.00 | -- | 4.14 | -- | 45.60 | -1.73 | -1.73 | 0.196 | 1.76 | 0.0508 | 4.84 | 4.16 | 44,560.00 | -44.99 | -35.49 | -58.93 | -42.98 | 74.28 | -- | -884.96 | -1,157.54 | 2.76 | -49.61 | 0.4075 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
| Eurofins-Cerep SA | 44.07m | 7.64m | 107.94m | 228.00 | 14.13 | 1.67 | 11.23 | 2.45 | 1,514.43 | 1,514.43 | 8,743.94 | 12,820.37 | 0.5864 | 1.67 | 5.08 | 193,287.10 | 10.16 | 14.21 | 12.22 | 17.51 | 85.01 | 73.61 | 17.33 | 19.77 | 4.87 | -- | 0.00005 | -- | -7.47 | 11.60 | -33.72 | 14.64 | -- | -- |
| Transgene SA | 7.63m | -22.33m | 135.20m | 158.00 | -- | 6.58 | -- | 17.71 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
| Cellectis SA | 17.59m | -88.47m | 149.23m | 235.00 | -- | 1.12 | -- | 8.48 | -1.39 | -1.11 | 0.2345 | 1.86 | 0.0619 | -- | 3.86 | 74,861.99 | -31.74 | -24.08 | -46.51 | -30.69 | -- | -64.64 | -513.02 | -308.24 | -- | -6.95 | 0.4142 | -- | -64.26 | -15.57 | -20.55 | -- | -26.15 | -- |
| Innate Pharma SA | 24.85m | -34.05m | 165.98m | 168.00 | -- | 5.76 | -- | 6.68 | -0.4215 | -0.4215 | 0.3078 | 0.3557 | 0.1418 | -- | 14.93 | 138,826.80 | -19.43 | -8.83 | -24.80 | -12.11 | 88.00 | 93.17 | -137.03 | -55.55 | -- | -- | 0.7527 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
| Ose Immunotherapeutics SA | 2.23m | -23.00m | 167.34m | 55.00 | -- | 7.21 | -- | 75.14 | -1.18 | -1.18 | 0.1138 | 1.06 | 0.0256 | -- | 3.22 | 40,490.91 | -26.46 | -17.17 | -33.15 | -20.55 | -- | -- | -1,032.87 | -94.71 | -- | -55.59 | 0.6659 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
| Genfit SA | 38.18m | -28.89m | 195.26m | 159.00 | -- | 2.87 | -- | 5.11 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| Nanobiotix SA | 36.22m | -33.47m | 218.98m | 102.00 | -- | -- | -- | 6.05 | -0.763 | -0.763 | 0.8429 | -0.4594 | 0.57 | -- | 17.20 | 355,107.80 | -52.68 | -54.11 | -323.15 | -80.68 | -- | -- | -92.42 | -756.15 | -- | -2.42 | 1.87 | -- | -- | 203.88 | 30.40 | -- | -7.81 | -- |
Data as of Sep 20 2024. Currency figures normalised to Cellectis SA's reporting currency: Euro EUR
5.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 30 Nov 2023 | 1.35m | 1.87% |
| CDC Croissance SAas of 16 May 2024 | 1.04m | 1.44% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 761.00k | 1.06% |
| Bessemer Investment Management LLCas of 30 Apr 2024 | 251.56k | 0.35% |
| KBC Fund Management Ltd.as of 31 Dec 2023 | 163.45k | 0.23% |
| Financi�re Arbevel SAas of 30 Dec 2022 | 126.34k | 0.18% |
| Saint Olive Gestion SNCas of 29 Dec 2023 | 85.00k | 0.12% |
| Wellington Management Co. LLPas of 30 Apr 2024 | 60.98k | 0.09% |
| Sunny Asset Management SAas of 27 Aug 2024 | 55.00k | 0.08% |
| Mercer Global Investments Europe Ltd.as of 31 Dec 2023 | 46.93k | 0.07% |
More ▼
Data from 16 May 2024 - 27 Aug 2024Source: FactSet Research Systems Inc.
